ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

ASH data presented by VelosBio — which drove the latest in a string of high wattage ADC deals — is building confidence in a target valued for its potential in both solid and hematological cancers.

While the lead indication for VelosBio’s Phase II-stage antibody-drug conjugate (ADC) VLS-101 is technically solid tumors, it was the Phase I hematological cancer data presented at the American Society of Hematology (ASH) meeting this weekend that sealed the deal for the company’s $2.8 billion takeout by Merck & Co. Inc. (NYSE:MRK) in November...